Skip to content
FacebookTwitterLinkedinYouTubeFlickrInstagram
  • enEnglish
    • esEspañol
    • caCatalà
GAEM
GAEM
Fundación Esclerosis Múltiple
  • MS online
  • Press room
  • Contact us
Top EN
 
  • Who are we?
    • Team
    • Objectives
    • Our commitment
  • What do we do?
    • We give support to innovation
    • Awareness actions
    • Events
  • Innovation
    • Project accelerator programme
    • Projects under way
    • Our calls
  • About MS
    • What are Multiple Sclerosis and Neuromyelitis Optica
    • Historical chronology of Multiple Sclerosis
    • Glossary
  • Get involved
    • Solidarity initiatives
    • Become a volunteer
  • Donate
    • Become a member
    • One-Off donations
    • Inheritances and legacies
  • Who are we?
    • Team
    • Objectives
    • Our commitment
  • What do we do?
    • We give support to innovation
    • Awareness actions
    • Events
  • Innovation
    • Project accelerator programme
    • Projects under way
    • Our calls
  • About MS
    • What are Multiple Sclerosis and Neuromyelitis Optica
    • Historical chronology of Multiple Sclerosis
    • Glossary
  • Get involved
    • Solidarity initiatives
    • Become a volunteer
  • Donate
    • Become a member
    • One-Off donations
    • Inheritances and legacies

Cell therapy for Multiple Sclerosis

Cell therapy uses cells instead of drugs or other mechanisms to prevent, treat or mitigate the disease

Cellular origin

Cells can be autologous (patient’s own cells), allogeneic (from a genetically similar but not identical donor) or xenogeneic (the donor cells are derived from a different species than the recipient). Autologous cells present a great advantage: being the patient’s own cells, rejection by the immune system and the consequent undesirable side effects are avoided.

Cellular type

On the other hand, cells can be specialized adult cells (such as dendritic cells) or stem cells (capable of differentiating into different cellullar types). Regardless of their origin or typology, the objective of cell therapy is to regenerate cells or cellular functions damaged by the disease by injecting cellular material, previously treated in the lab, into the patient.

It is a promising therapeutic strategy in order to improve neuroprotective mechanisms and induce neuroregeneration in multiple sclerosis.

 

Therapy with specialized adult cells

Our body is made up of different tissues and millions of cells that come from a single one, the zygote, which will develop into an embryo. As the embryo continues to develop, it will subsequently become a new individual.

The zygote has the capacity or “power” to generate any cell type; it is, therefore, “totipotent”.

Otherwise, most cells that form an adult organism have lost this “totipotent” capacity, since they have specialized in a specific cell type (neuron, skin cell, lymphocyte, etc.). They have become specialized adult cells.

One type of specialized adult cells of interest in cellular therapy for MS are the dendritic cells or “antigen presenting cells”. They are part of the immune system and control its activity.

How do they do that? Dendritic cells (DC) have the ability to capture antigens (proteins recognized as foreign by the immune system) and present them to T or B lymphocytes, thus regulating their immune response.

On the other hand, immature DCs have another optimal characteristic: “functional plasticity”. Depending on the environment in which they mature, DCs can create immunity (prompt the immune system to attack) or tolerance (regulate the response of the immune system to prevent it from attacking). They would, therefore, become immunogenic DCs or regulatory DCs respectively, as shown in the following image.

The project  “Antigen-specific immune tolerance therapy with dendritic cells”, currently being carried out at the IDIBAPS / Hospital Clínic of Barcelona, ​​bases its research on the maturation of immature DC (obtained from the differentiation of monocytes extracted from the patient’s blood) in a tolerogenic environment in the lab in order to obtain tolerogenic or regulatory DC. Next, the cells are treated with myelin proteins and administered intravenously to the patient to “reeducate” or induce tolerance towards myelin to the rest of the immune system.

This tolerization process is key for the immune system to fail to recognize myelin as foreign and to attack it.

The objective of this therapy is to modulate the patient’s defenses in a specific and selective way, to prevent or stop the inflammation caused by antigen-specific T-lymphocytes without altering the rest of the defenses, so that adverse side effects are diminished.

Another example of a study that uses dendritic cells as cellular therapy is the one carried out in Hospitals Germans Trias I Pujol which, unlike the previous one, treats DCs with vitamin D3.

 

Esclerosis Múltiple y Neuromielitis Óptica

 

 

 


 

Read more…

 

Genetic therapy for MS (coming soon…)

 

21 March 2018Leave a comment

Related posts:

Yo Doy mis Pasos (I make my steps), new and innovative campaign for Multiple Sclerosis
19 November 2018
Javier Sardá, la voz de la campaña por la esclerosis múltiple “Yo Doy mis Pasos”
5 November 2018
GAEM supports reseach in the World Day of Multiple Sclerosis
2 May 2018
NEW THERAPEUTICAL STRATEGIES IN MULTIPLE SCLEROSIS
23 February 2018
CURRENT THERAPIES FOR MULTIPLE SCLEROSIS
26 January 2018
THE DIAGNOSIS OF MULTIPLE SCLEROSIS
18 December 2017

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

clear formPost comment

Search
Entradas recientes
  • Yo Doy mis Pasos (I make my steps), new and innovative campaign for Multiple Sclerosis
    19 November 2018
  • Javier Sardá, la voz de la campaña por la esclerosis múltiple “Yo Doy mis Pasos”
    5 November 2018
  • GAEM supports reseach in the World Day of Multiple Sclerosis
    2 May 2018
  • Cell therapy for Multiple Sclerosis
    21 March 2018
  • NEW THERAPEUTICAL STRATEGIES IN MULTIPLE SCLEROSIS
    23 February 2018
  • CURRENT THERAPIES FOR MULTIPLE SCLEROSIS
    26 January 2018
Tweets by @fundaciongaem

We subscribe the principles of HONcode. Check it here;. We subscribe the principles of HONcode.
Check it here.

Search only in health websites certified by HONcode:

Web Médica Acreditada. Ver más información
SSL Secure

Foundation linked to the

Parc Científic de Barcelona

Federated with

Esclerosis Múltiple España

Collaborators with REEM

REEM

Collaborating companies and organisations

AE Fundraising
AE Fundraising
Ajuntament
Ajuntament
Cadena Movitel
Cadena Movitel
Diputació
Diputació
ecom
ecom
euromadi
euromadi
gencat
gencat
labalear
labalear
novartis
novartis
once
once
scacs
scacs
BBVA
BBVA
obra social 2
obra social 2
almirall
almirall
merck
merck
mutua
mutua
palex
palex
hollister
hollister

Supporting companies and organisations

guttmann
guttmann
hac
hac
CAF
CAF
ub
ub
altiria
altiria

GAEM
Parc Científic Barcelona
Baldiri Reixac, 4
Torre R 2ª planta
08028 Barcelona
Tel. +34 935 190 300
Whatsapp: +34 608 692 827
info@fundaciongaem.org

  • Accessibility
  • Legal notice
  • Privacy policy
Legal EN

Copyright © GAEM FOUNDATION 2017 - All rights reserved.

IMPORTANT INFORMATION ON COOKIES: This Website uses cookies to provide a better service. To continue browsing accepts its use. You will find more information in our Cookies Policy.

Accept CookiesModify settings